Opus Genetics (IRD) Stock Forecast & Price Target

Opus Genetics is attractive because its lead gene-therapy assets, OPGx-LCA5 and OPGx-BEST1, have moved from proof-of-concept toward registrational and pivotal paths with FDA-aligned microperimetry endpoints, and both programs have generated encouraging early functional and imaging signals. The company also has a meaningful near-term funding cushion from a $10M milestone expected in 4Q26, up to $130M in total milestones, an undisclosed low-teens royalty stream, and runway into 2029 without relying on PRV monetization, while its 2Q26 cash balance was $89. Beyond the lead assets, the broader pipeline is funded within current runway and could create multiple catalysts, with RDH12 and MERTK clinical entries and four clinical data readouts during 2027 supporting a diversified, high-upside platform.

Opus Genetics is a high-risk clinical-stage company whose lead assets, OPGx-LCA5 and OPGx-BEST1, still rest on small, early, and partly uncontrolled datasets, so reported efficacy and durability may not hold in larger or longer studies. Its regulatory and commercial path is equally uncertain because FDA alignment does not ensure approval, ultra-rare IRDs make patient identification, physician adoption, and reimbursement difficult, and the company has no prior commercial launch experience. Financially, it has incurred significant losses since inception, depends mainly on development-stage assets and one partnered revenue-generating product, and may need additional capital despite a cash runway expected to extend into 2029, creating dilution risk.